Novartis takes on Sanofi, Amgen with $9.7 billion takeover of heart drug maker
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Monday
February 06, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
MONDAY, FEBRUARY 06, 2023
Novartis takes on Sanofi, Amgen with $9.7 billion takeover of heart drug maker

World+Biz

Reuters
25 November, 2019, 03:00 pm
Last modified: 25 November, 2019, 03:01 pm

Related News

  • Ample awareness needed at all levels to increase Biologic use: Experts
  • Healthcare companies Sanofi and GSK to seek Covid-19 vaccine regulatory approval
  • Novartis working on pan-coronavirus oral treatment, CEO says
  • Novartis may divest generic unit Sandoz as price pressures mount
  • Beximco Pharma completes Sanofi acquisition

Novartis takes on Sanofi, Amgen with $9.7 billion takeover of heart drug maker

Novartis shares were seen up 0.2%, premarket indicators showed

Reuters
25 November, 2019, 03:00 pm
Last modified: 25 November, 2019, 03:01 pm
Novartis takes on Sanofi, Amgen with $9.7 billion takeover of heart drug maker

Swiss drugmaker Novartis (NOVN.S) is betting on heart drug prospect inclisiran in a $9.7 billion takeover of The Medicines Co (MDCO.O) as it challenges cardiovascular medicines from Amgen Inc (AMGN.O), Sanofi (SASY.PA) and Regeneron Pharmaceuticals (REGN.O).

Novartis is paying $85 per share in cash, a 24% premium over The Medicines Co's closing price of $68.55 on Friday, to acquire the U.S. biotechnology company's lone drug, the cholesterol-lowering injection inclisiran.

The deal shows Novartis CEO Vas Narasimhan is ready to spend billions on not just rare disease treatments, as it did in 2018 when it paid $8.7 billion for gene therapy specialist AveXis, but also for cardiovascular medicines aimed at a market with potentially millions of patients.

Inclisiran, which still must win regulators' approval, is set to require twice-yearly injections by doctors, far less frequently than the 26-injection regimens of Amgen's Repatha and Sanofi's and Regeneron's Praluent cholesterol-lowering drugs.

"We believe that will lead to less patient abandonment," Narasimhan told investors on a call on Monday. "Payers will have confidence knowing that physician administration will ensure patient compliance."

Novartis shares were seen up 0.2%, premarket indicators showed. JBPRE01

Repatha and Praluent, which similar to inclisiran aim to inhibit PCSK9 proteins that lead to elevated levels of bad LDL cholesterol in people with heart disease, have struggled to gain traction due a demanding dosing regiment as well as objections to their price, which makers have been forced to slash to less than $6,000 annually.

Narasimhan said he is confident that inclisiran can produce an attractive return on investment and contribute to sales starting in 2021, contingent upon regulatory approval and completion of the deal.

"We see returns well in excess of cost of capital," Chief Financial Officer Harry Kirsch said. Novartis plans to pay for with one-third cash and two-thirds long-term borrowings.

Inclisiran could become one of its best-selling medicines, Basel-based Novartis predicted, adding the transaction had been approved by the boards of both companies.

The acquisition would modestly dilute core earnings per share versus a no-deal scenario during the next few years, but should then be significantly accretive to group core operating income and core EPS in the medium term, Novartis said.

HEART DISEASE

Inclisiran, for use on top of statins by heart patients who struggle to lower their cholesterol levels with traditional therapy, is seen as complementing Novartis's growing business with its heart-failure medicine Entresto, which topped the $1 billion annual revenue threshold last year.  

Narasimhan said the company can leverage the sales force it built up to help boost the initially slow Entresto sales to market inclisiran, too.

Novartis has historically had a strong cardiovascular drug franchise, but lost ground when Diovan, once a $6 billion-per-year seller, lost patent protection in 2012. It left the company without an immediate, innovative follow-up product.

The deal fits Narasimhan's target of acquisitions of up to $10 billion to bolster the group's portfolio of medicines with new products or technologies.

Novartis' hunt for deals comes as billions in revenue is under threat from upcoming patent expirations including on Lucentis, for macular degeneration, iron overload medicine Exjade and $3.3 billion-per-year MS drug Gilenya.

Still, Novartis said it is confident that new products including inclisiran will help bolster growth and profitability.

It expects to expand core operating income margins in its Innovative Medicines division to the "mid-thirties" in the near term and to the "mid-to high-thirties" in the medium term.

Global Economy

Novartis / Sanofi / Amgen

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • GDP growth drops to 7.1% in FY22, per capita income $2,793
    GDP growth drops to 7.1% in FY22, per capita income $2,793
  • Consumers should pay actual costs to get gas, electricity: PM
    Consumers should pay actual costs to get gas, electricity: PM
  • Dr Debapriya Bhattacharya. Illustration: TBS
    Development won't sustain sans political consensus: Debapriya 

MOST VIEWED

  • People wait for their turn to buy low-priced bun-kabab from a shop in Karachi, Pakistan June 10, 2022. REUTERS/Akhtar Soomro
    Pakistan is on the brink: Financial Times
  • Picture: Collected
    IMF combing 'every book, every subsidy' during negotiations: Pak PM
  • Photo: Reuters
    Pakistan's largest oil refinery shuts down
  • Iran's Supreme Leader Ayatollah Ali Khamenei speaks during a meeting with a group of girls who reached the age of puberty in Tehran, Iran February 3, 2023. Office of the Iranian Supreme Leader/WANA (West Asia News Agency)/Handout via REUTERS
    Iran's supreme leader issues pardon for 'tens of thousands' of prisoners
  • Photo: Reuters
    At least 23 dead as dozens of wildfires torch forests in Chile
  • Oil’s New Map: How India turns Russia crude into the west's fuel
    Oil’s New Map: How India turns Russia crude into the west's fuel

Related News

  • Ample awareness needed at all levels to increase Biologic use: Experts
  • Healthcare companies Sanofi and GSK to seek Covid-19 vaccine regulatory approval
  • Novartis working on pan-coronavirus oral treatment, CEO says
  • Novartis may divest generic unit Sandoz as price pressures mount
  • Beximco Pharma completes Sanofi acquisition

Features

Say it with Colours

Say it with Colours

13h | Mode
Photo: Courtesy

From 'Made in Bangladesh' to 'Designed in Bangladesh'

15h | Panorama
Google must adjust to a world where content is increasingly generated by AI. Photo: Bloomberg

Google will join the AI wars, pitting LaMDA against ChatGPT

11h | Panorama
The megaproject Rooppur Nuclear Power Plant has a debt of Tk90,474 crore. Photo: Courtesy

Projects funded with debt need to be selected prudently, and implemented timely

13h | Panorama

More Videos from TBS

ICB to withdraw Padma Bank Investment as return

ICB to withdraw Padma Bank Investment as return

5h | TBS Insight
Kiara Advani & Sidharth Malhotra's Wedding Update

Kiara Advani & Sidharth Malhotra's Wedding Update

5h | TBS Entertainment
What you probably didn't know about CR7

What you probably didn't know about CR7

3h | TBS SPORTS
US shoots down Chinese spy balloon

US shoots down Chinese spy balloon

4h | TBS World

Most Read

1
Leepu realised his love for cars from a young age and for the last 40 years, he has transformed, designed and customised hundreds of cars. Photo: Collected
Panorama

'I am not crazy about cars anymore': Nizamuddin Awlia Leepu

2
The International Monetary Fund (IMF) logo is seen outside the headquarters building in Washington, U.S., September 4, 2018. REUTERS/Yuri Gripas/File Photo
Economy

IMF approves $4.7 billion loan for Bangladesh, calls for ambitious reforms

3
Fund cut as Dhaka's fast-track transit projects on slow spending lane
Infrastructure

Fund cut as Dhaka's fast-track transit projects on slow spending lane

4
Photo: Collected
Court

Japanese mother gets guardianship of daughters, free to leave country

5
Belal Ahmed new acting chairman of SIBL
Banking

Belal Ahmed new acting chairman of SIBL

6
Photo: Collected
Startups

ShopUp secures $30m debt financing to boost expansion, supply chain

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]